SG11201903517RA - Composition for alleviating or treating pain - Google Patents
Composition for alleviating or treating painInfo
- Publication number
- SG11201903517RA SG11201903517RA SG11201903517RA SG11201903517RA SG11201903517RA SG 11201903517R A SG11201903517R A SG 11201903517RA SG 11201903517R A SG11201903517R A SG 11201903517RA SG 11201903517R A SG11201903517R A SG 11201903517RA SG 11201903517R A SG11201903517R A SG 11201903517RA
- Authority
- SG
- Singapore
- Prior art keywords
- alleviating
- composition
- treating pain
- pain
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/01—Carboxy-lyases (4.1.1)
- C12Y401/01015—Glutamate decarboxylase (4.1.1.15)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/30—Animals modified by surgical methods
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Psychology (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160143519 | 2016-10-31 | ||
| PCT/KR2017/012136 WO2018080277A1 (en) | 2016-10-31 | 2017-10-31 | Composition for alleviating or treating pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201903517RA true SG11201903517RA (en) | 2019-05-30 |
Family
ID=62023801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201903517RA SG11201903517RA (en) | 2016-10-31 | 2017-10-31 | Composition for alleviating or treating pain |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190255152A1 (en) |
| EP (1) | EP3533471B1 (en) |
| JP (1) | JP6957614B2 (en) |
| KR (2) | KR20190067815A (en) |
| CN (1) | CN110461367B (en) |
| AU (1) | AU2017351914B2 (en) |
| BR (1) | BR112019008788A2 (en) |
| CA (2) | CA3123063A1 (en) |
| CL (1) | CL2019001106A1 (en) |
| ES (1) | ES2905227T3 (en) |
| RU (1) | RU2725830C1 (en) |
| SA (1) | SA519401667B1 (en) |
| SG (1) | SG11201903517RA (en) |
| WO (1) | WO2018080277A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210275614A1 (en) * | 2018-10-25 | 2021-09-09 | Takeda Pharmaceutical Company Limited | Aav triple-plasmid system |
| EP3927728A2 (en) | 2019-02-21 | 2021-12-29 | Xencor, Inc. | Untargeted and targeted il-10 fc-fusion proteins |
| CA3180304A1 (en) * | 2020-05-28 | 2021-12-02 | Kenan Christopher GARCIA | Engineered interleukin-10 polypeptides and uses thereof |
| JP2024512414A (en) * | 2021-03-12 | 2024-03-19 | コーロン ライフ サイエンス インコーポレイテッド | Composition for preventing or treating neurodegenerative diseases |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7261882B2 (en) * | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
| KR20070100241A (en) * | 2004-10-28 | 2007-10-10 | 유니버시티 오브 피츠버그 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain |
| RU2433825C2 (en) * | 2004-12-06 | 2011-11-20 | Медисинова, Инк. | Method of treating neuropathic pain and associated with it syndromes |
| US7527785B2 (en) * | 2005-05-31 | 2009-05-05 | Neurologix, Inc. | Glutamic acid decarboxylase (GAD) chimera and methods of use |
| WO2008010637A1 (en) * | 2006-07-19 | 2008-01-24 | Industry-Academic Cooperation Foundation, Yonsei University | Composition for attenuating neuropathic pain comprising a recombinant vector expressing gad65 |
| KR20080007968A (en) * | 2006-07-19 | 2008-01-23 | 연세대학교 산학협력단 | Composition for attenuating neuropathic pain comprising a recombinant vector expressing gad65 |
| FI20070808A0 (en) * | 2007-10-25 | 2007-10-25 | Mart Saarma | Split variants of GDNF and uses thereof |
| CN101586096A (en) * | 2008-05-21 | 2009-11-25 | 王尚武 | Recombinant virus with coexpression of anthropogenic glutamate decarboxylase and cell factor |
| EP2457579A1 (en) * | 2010-11-26 | 2012-05-30 | Technische Universität Dresden | Covalently linked interleukin -10 |
| TW201527322A (en) * | 2011-02-08 | 2015-07-16 | Abbvie Inc | Treatment of osteoarthritis and pain |
| KR20170034701A (en) * | 2015-09-21 | 2017-03-29 | 코오롱생명과학 주식회사 | Composition for treating pain |
-
2017
- 2017-10-31 US US16/346,170 patent/US20190255152A1/en active Pending
- 2017-10-31 SG SG11201903517RA patent/SG11201903517RA/en unknown
- 2017-10-31 JP JP2019523609A patent/JP6957614B2/en active Active
- 2017-10-31 KR KR1020197011633A patent/KR20190067815A/en not_active IP Right Cessation
- 2017-10-31 CA CA3123063A patent/CA3123063A1/en active Pending
- 2017-10-31 CA CA3041980A patent/CA3041980C/en active Active
- 2017-10-31 ES ES17863851T patent/ES2905227T3/en active Active
- 2017-10-31 KR KR1020217026063A patent/KR102445192B1/en active IP Right Grant
- 2017-10-31 WO PCT/KR2017/012136 patent/WO2018080277A1/en unknown
- 2017-10-31 EP EP17863851.6A patent/EP3533471B1/en active Active
- 2017-10-31 RU RU2019116751A patent/RU2725830C1/en active
- 2017-10-31 BR BR112019008788A patent/BR112019008788A2/en unknown
- 2017-10-31 AU AU2017351914A patent/AU2017351914B2/en active Active
- 2017-10-31 CN CN201780081884.XA patent/CN110461367B/en active Active
-
2019
- 2019-04-23 CL CL2019001106A patent/CL2019001106A1/en unknown
- 2019-04-28 SA SA519401667A patent/SA519401667B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102445192B1 (en) | 2022-09-20 |
| CA3041980A1 (en) | 2018-05-03 |
| ES2905227T3 (en) | 2022-04-07 |
| JP6957614B2 (en) | 2021-11-02 |
| EP3533471A1 (en) | 2019-09-04 |
| EP3533471A4 (en) | 2020-05-06 |
| CL2019001106A1 (en) | 2019-08-16 |
| CN110461367A (en) | 2019-11-15 |
| KR20210107140A (en) | 2021-08-31 |
| SA519401667B1 (en) | 2023-01-11 |
| KR20190067815A (en) | 2019-06-17 |
| WO2018080277A1 (en) | 2018-05-03 |
| AU2017351914B2 (en) | 2020-09-10 |
| CA3041980C (en) | 2023-06-13 |
| US20190255152A1 (en) | 2019-08-22 |
| JP2019537595A (en) | 2019-12-26 |
| CN110461367B (en) | 2023-05-26 |
| RU2725830C1 (en) | 2020-07-06 |
| EP3533471B1 (en) | 2022-01-19 |
| BR112019008788A2 (en) | 2019-07-16 |
| CA3123063A1 (en) | 2018-05-03 |
| AU2017351914A1 (en) | 2019-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201705093UA (en) | Composition for treating il-6-related diseases | |
| IL262825A (en) | Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions | |
| SI3261726T1 (en) | Composition for the treatment of acne | |
| IL290150A (en) | Compositions and methods for the treatment of chronic pain | |
| IL262419A (en) | Cannabis-enriched enzymatically treated therapeutic composition | |
| ZA201707737B (en) | Composition for treating brain lesions | |
| ZA201803320B (en) | Pharmaceutical compositions for treating pain | |
| SG11201903517RA (en) | Composition for alleviating or treating pain | |
| ZA201807858B (en) | Plant treatment composition | |
| HK1248130A1 (en) | Composition for treating pain | |
| EP3373947A4 (en) | Compounds and methods for treating pain | |
| GB201604658D0 (en) | Treatment for pain | |
| EP3432884A4 (en) | Combination for treating pain | |
| PL3303486T3 (en) | Surface treatment composition | |
| PL3129031T3 (en) | Composition for treating stomach pain | |
| ZA201805215B (en) | Preparation for nasal-nasopharyngeal treatment | |
| EP3297443A4 (en) | Herbal composition for treatment of back pain | |
| PL3273997T3 (en) | Compositions for the treatment of cold | |
| GB201505205D0 (en) | Treatment for pain | |
| GB201504688D0 (en) | Treatment for pain | |
| PT3524255T (en) | Composition for the treatment of acne |